Clinical Trial Update: Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation [Phase 2]

View source ↗

Summary

This notice describes a Phase 2 clinical trial evaluating avapritinib for relapsed or refractory pediatric core-binding factor acute myeloid leukemia with KIT m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Core-binding Factor Acute Myeloid Leukemia

Drugs mentioned

• Avapritinib (avapritinib)

Snippet

Sponsor: Children's Hospital of Soochow University | Conditions: AML, Childhood, Relapse/Recurrence | Phase 2 | Status: RECRUITING